Armata Pharmaceuticals Inc. (TG1N)
XFRA 
Summary
TG1N Chart
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.42 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.15 per share a year ago.
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?
Armata Pharmaceuticals (ARMP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
All You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy
Armata Pharmaceuticals (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Armata Pharmaceuticals Inc. (TG1N) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Armata Pharmaceuticals Inc. ever had a stock split?
Armata Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Deborah L. Birx CEO | XFRA Exchange | US04216R1023 ISIN |
| US Country | 60 Employees | - Last Dividend | 10 May 2019 Last Split | 9 Mar 2011 IPO Date |
Overview
Armata Pharmaceuticals, Inc. is a pioneering entity in the realm of biotechnology, concentrating its efforts on the frontier of developing targeted bacteriophage therapeutics aimed at combating antibiotic-resistant infections on a global scale. With a foundation rested on its proprietary bacteriophage-based technology, the company stands as a beacon of innovation within the clinical-stage sphere. Its significant endeavor is underscored by its strategic research collaboration agreement with Merck Sharp & Dohme Corp., focusing on the cultivation of synthetic bacteriophage candidates to engage undisclosed infectious disease agents. Base operations are anchored in Los Angeles, California, marking its strategic positioning. As a vital subsidiary of Innoviva, Inc., Armata Pharmaceuticals, Inc. weaves a significant narrative in advancing medical science against the backdrop of escalating antibiotic resistance worldwide.
Products and Services
Armata Pharmaceuticals, Inc. distinguishes itself through an ambitious portfolio of product candidates, each harnessing the potential of bacteriophage technology to confront different bacterial challenges. Below is a highlight of its innovative foray into bacteriophage therapeutics:
- AP-SA02: This candidate targets the formidable Staphylococcus aureus bacteremia, an infection that poses significant risks and challenges in the current antibiotic-resistant landscape. Through the precision of bacteriophage technology, AP-SA02 seeks to provide a viable and effective treatment option where traditional antibiotics may fail.
- AP-PA02: Dedicated to addressing infections caused by Pseudomonas aeruginosa, AP-PA02 embodies the targeted approach of Armata Pharmaceuticals. This pathogen, known for its role in critical infections such as in cystic fibrosis patients, illustrates the urgent need for alternative therapeutic options that this candidate aims to fulfill.
- AP-PA03: Focused on the treatment of pneumonia, AP-PA03 represents another facet of Armata’s commitment to developing bacteriophage-based solutions. Considering the global burden of pneumonia, especially in vulnerable populations, this candidate could significantly impact public health outcomes through successful development and deployment.
With each of these product candidates, Armata Pharmaceuticals, Inc. showcases its dedication to leveraging the nuanced mechanisms of bacteriophages to challenge the current paradigms of infectious disease treatment, particularly those involving resistant strains of bacteria.
Contact Information
